DNA with a twist: New company to search for cancer drugs and antibiotics

A new company has joined the fight against MRSA and cancer. Researchers at the John Innes Centre (Norwich) have launched a new company, Inspiralis Ltd, based around their expertise in DNA topoisomerases – a group of enzymes that help DNA molecules to unravel and wind up properly and not to become tangled during replication.

“DNA becomes tangled as a result of various cellular processes, such as replication, which ultimately stops these processes continuing. DNA topoisomerases untangle it. Without them cells die”, says Inspiralis co-founder Dr Nicolas Burton.

Topoisomerases are already targets for several drugs, including anti-tumour drugs and antibiotics, such as ciprofloxacin – the anti-anthrax drug. The search is now on for new ways of inhibiting them. Inspiralis Ltd make a range of products targeted to the pharmaceutical industry to enable drug-discovery work in this area including topoisomerase enzymes themselves as well as associated products.

A new high-throughput assay, developed recently in the laboratory of Prof. Tony Maxwell of the John Innes Centre (and co-founder of Inspiralis), will also provide a huge advance on the standard gel-based screening method for topoisomerase inhibitors. Inspiralis Ltd will develop the technique further as well as offering screening services to companies. “The assay will potentially allow millions of compounds to be screened for activity rather than just hundreds”, says Dr Burton.

The technology can now be accessed as a service or as a kit helping pharmaceutical companies and academics to screen for new and better cancer drugs and antibiotics.

Some powerful antibiotics and key anti-cancer drugs act by inhibiting topoisomerases. In cancer, cells rapidly divide in an uncontrolled manner and topoisomerase inhibitors can block this uncontrolled cell division.

“Topoisomerase inhibitors are key targets for new drug development”, says Mrs Alison Howells (co-founder). “We can test potential new drugs against topoisomerases as well as help discover new inhibitors as a first step to developing brand new drugs”.

Inspiralis is based at the Norwich Bio-Incubator at JIC and was founded with backing from the ICENI fund, a private investor and the John Innes Centre.

The high-throughput assay is patented by JIC’s and BBSRC’s technology transfer company, Plant Biosciences Ltd, and non-exclusive licenses have already been granted to pharmaceutical companies.

Source: Norwich BioScience Institutes

Related stories:

First look at an enzyme target for antibacterial and cancer drugs
The veil has finally been lifted on an enzyme that is critical to the process of DNA transcription and replication, and is a prime target of antibacterial and anticancer drugs. Researchers with the U.S. Department of Energy’s Lawrence Berkeley National Laboratory and the University of California at Berkeley have produced the first three-dimensional structural images of a DNA-bound Type II topoisomerase (topo II) that is responsible for untangling coiled strands of the chromosome during cell division.
Pill that boosts productivity gaining favor, raising concerns among medical ethicists
In a place like Silicon Valley, where career prospects often hinge on a person's intelligence and ability to work hellishly long hours, "brain doping" probably was inevitable.
FDA posts list of potential problem drugs
(AP) -- The government on Friday began posting a list of prescription drugs under investigation for potential safety problems, in an effort to better inform doctors and patients.
Best way to treat malaria: Avoid using same drug for everyone, scientists say
(PhysOrg.com) -- A team of scientists employing a sophisticated computer model pioneered at Princeton University and Resources for the Future has found that many governments worldwide are recommending the wrong kind of malaria treatment.
1 step back ... 2 steps forward
Women with hormone-receptor positive, metastatic breast cancer may take medications for years to help keep their cancer at bay, but when the tumor becomes resistant to anti-hormonal drugs, treatment with chemotherapy becomes the only option. But a study presented today at the 2008 ASCO Breast Cancer Symposium may change this approach. Early data suggests a new treatment approach can "re-sensitize" the tumor, allowing anti-hormonal drugs to do their job once again.
Atomic structure of the mammalian 'fatty acid factory' determined
Mammalian fatty acid synthase is one of the most complex molecular synthetic machines in human cells. It is also a promising target for the development of anti-cancer and anti-obesity drugs and the treatment of metabolic disorders. Now researchers at ETH Zurich have determined the atomic structure of a mammalian fatty acid synthase. Their results have just been published in Science magazine.
Free drug samples may end up costing uninsured more
Free drug samples provided to physicians by pharmaceutical companies could actually be costing uninsured patients more in the long run, according to a study done by researchers at Wake Forest University Baptist Medical Center and colleagues.
A light bulb and a few chemicals: Scientists find a way to help make new reactions
(PhysOrg.com) -- Princeton scientists have discovered a way of stimulating organic molecules that they expect will prompt researchers to create materials from new kinds of chemical reactions.

News discussion:

Medicine & Health news